Autologous Adipose-Derived Regenerative Cells for Therapeutic Angiogenesis

Author(s): Toyoaki Murohara, Satoshi Shintani, Kazuhisa Kondo

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 24 , 2009

Become EABM
Become Reviewer
Call for Editor


Therapeutic angiogenesis is an important means to salvage tissues against severe ischemic diseases in patients with no option for other vascular intervention. A number of recent studies implicated potentials of cell-based therapeutic angiogenesis using autologous bone marrow mononuclear cells, CD34+ cells, peripheral blood mononuclear cells, and so on. Subcutaneous adipose tissues can be harvested by relatively easy methods. Recent studies indicated that adipose tissues contain progenitor cells or regenerative cells that can give rise to several mesenchymal lineages. Moreover, these progenitor cells can release multiple angiogenic growth factors and cytokines/chomokines including vascular endothelial growth factor (VEGF), hypatocyte growth factor (HGF) and chemokine stromal cell-derived factor-1 (SDF-1). The combination of these biological properties of adipose-derived regenerative cells (ADRCs) implicates that autologous adipose tissue will be a useful cell source for therapeutic angiogenesis in the next generation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [2784 - 2790]
Pages: 7
DOI: 10.2174/138161209788923796
Price: $65

Article Metrics

PDF: 11